

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
THERION BIOLOGICS CORPORATION	02/27/2007

<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
<b>Street Address:</b>	6011 EXECUTIVE BOULEVARD, SUITE 325
<b>Internal Address:</b>	OFFICE OF TECHNOLOGY TRANSFER
<b>City:</b>	ROCKVILLE
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	20852

**PROPERTY NUMBERS Total: 40**

Property Type	Number
Application Number:	07695024
Application Number:	07879649
Application Number:	08238611
Application Number:	08270106
Application Number:	08317402
Application Number:	08396385
Application Number:	08500306
Application Number:	08686280
Application Number:	08686281
Application Number:	09287221
Application Number:	09366670
Application Number:	09693121
Application Number:	09856988

**CH \$1600.00 07695024**

Application Number:	10057136
Application Number:	10197127
Application Number:	10297168
Application Number:	10406317
Application Number:	10543944
Application Number:	10579007
Application Number:	10579025
Application Number:	10660369
Application Number:	11321868
Application Number:	60038253
Application Number:	60111582
Application Number:	60211717
Application Number:	60410161
Application Number:	60448591
Application Number:	60519354
Application Number:	60519427
PCT Number:	US0119201
PCT Number:	US0405077
PCT Number:	US0437810
PCT Number:	US0438643
PCT Number:	US9505487
PCT Number:	US9512638
PCT Number:	US9610837
PCT Number:	US9712203
PCT Number:	US9712546
PCT Number:	US9803693
PCT Number:	US9926866

**CORRESPONDENCE DATA**

Fax Number: (312)616-5700  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 312-616-5600  
Email: assignments@leydig.com  
Correspondent Name: JULIE J. HONG  
Address Line 1: 180 N STETSON AVE SUITE 4900  
Address Line 2: 623907  
Address Line 4: CHICAGO, ILLINOIS 60601-6731

ATTORNEY DOCKET NUMBER:

623907

NAME OF SUBMITTER:

JULIE J HONG

**Total Attachments: 10**

source=Therion\_DHHS\_D#page1.tif  
source=Therion\_DHHS\_D#page2.tif  
source=Therion\_DHHS\_D#page3.tif  
source=Therion\_DHHS\_D#page4.tif  
source=Therion\_DHHS\_D#page5.tif  
source=Therion\_DHHS\_D#page6.tif  
source=Therion\_DHHS\_D#page7.tif  
source=Therion\_DHHS\_D#page8.tif  
source=Therion\_DHHS\_D#page9.tif  
source=Therion\_DHHS\_D#page10.tif

**PATENT**

Leydig, Voit & Mayer, Ltd.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-673 1

**ASSIGNMENT**

**WHEREAS**, Therion Biologics Corp. of 222 Third Street, Suite 2300, Cambridge, Massachusetts, 02142 USA (hereinafter referred to as Assignor), co-owns certain inventions for which patent applications were executed for patents, as identified in the Attachment hereto, and

**WHEREAS**, the Government of the United States of America (hereinafter referred to as Assignee) is desirous of acquiring the Assignor's right, title, and interest in and under the inventions described in the patent applications identified in the Attachment hereto or otherwise co-owned with an employee of the United States.

**NOW THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor assigns and transfers to the Assignee, represented by the Secretary, Department of Health and Human Services, the full and exclusive rights, title, and interest in and to (a) the patents, patent applications, and inventions identified in the Attachment hereto, or otherwise co-owned with an employee of the United States, whether filed in the United States or elsewhere (e.g., in any region or country of the world), (b) other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, PCT applications, national phase applications, petty patent applications, and utility model applications) that may be filed in the United States or elsewhere (e.g., in any region or country of the world) on the inventions identified in the Attachment hereto and/or that claim priority to any of the patents and patent applications identified in the Attachment hereto, and (c) the patents, extensions, or derivations thereof that may issue on or from any of the aforementioned patents and patent applications.

**ASSIGNOR HEREBY AUTHORIZES** and requests the Commissioner of Patents to issue U.S. patents to the above-mentioned Assignee agreeably with the terms of this assignment document.

**ASSIGNOR ALSO HEREBY AUTHORIZES** the Assignee to insert into this assignment document (e.g., into the Attachment hereto) the filing date and application number of any patent application identified in the Attachment hereto or otherwise co-owned with an employee of the United States for which the filing date and particulars (e.g., patent number and/or patent application number) are unavailable at the time this assignment document is executed.

**UPON SAID CONSIDERATION**, Assignor conveys to the Assignee the right to make application in its own behalf for protection of the invention in the U.S. and elsewhere (i.e., in any countries) and to claim under the Patent Cooperation Treaty, the International Convention, and/or other international arrangement for any such patent application the date of the U.S. application (or any other patent application on the invention) to gain priority with respect to other patent applications.

**ASSIGNOR DOES HEREBY COVENANT** and agree with the Assignee that it will not execute any writing or do any act whatsoever conflicting with the terms of this assignment document set forth herein, and that Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee and subject to the terms of this Settlement Agreement, execute such

Exhibit D 1 of 10

**PATENT**

**REEL: 019020 FRAME: 0237**

additional assignments and other writings as may be necessary to perfect the Assignee's enjoyment of this assignment, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of, the assigns and legal representatives of all parties hereto.

IN WITNESS WHEREOF, the undersigned has set his hand on the date shown below.

Date 2/27/07

Michael S. Wyand  
Signature of Authorized Officer  
Therion Biologics Corp.

Michael S. Wyand  
Printed Name of Authorized Officer  
Therion Biologics Corp.

President CEO  
Title of Authorized Officer  
Therion Biologics Corp.

STATE OF MA  
COUNTY OF Middlesex

On this 27 day of Feb, 2007, before me, a Notary Public in and for said county, appeared \_\_\_\_\_, who is personally known to me to be the same person whose name is

subscribed to the foregoing assignment document, and acknowledged that he/she signed and delivered the document as his/her free and voluntary act for the uses and purposes therein set forth.

PREMA K MATTHEWS  
Notary Public

My commission  
Expires: June 16, 2011

{SEAL}

100159939\_1.DOC




Exhibit D 2 of 10

THELION CASE LIST - JOINTLY OWNED

Application Serial No	Filing Date	Title	Next Action	Final Due Date	Client Ref. No.	NI Matter No.	I.C./CO-OWNED
10660369	9/11/2003	TRANSDUCCED NEOPLASTICE CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY .....	Response to non-final OA TRANSFERRED TO E&A ON 11/02/2006 per NIH request INSTRUCTIONS TO PREPARE AN AMENDMENT BY 12/20 CONVEYED TO AND CONFIRMED BY E&A ON 12/04/2006	12/20/2006		054440-US	NIH
50884498	7/15/1997	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to Office Action or Request for Extension	1/3/2007	TBC-1025-JP	046570-JP	NIH
111317.5	6/26/1996	GENERATION OF IMMUNE RESPONSE TO PROSTATE SPECIFIC ANTIGEN (PAS)	Response to Office Action or Request for Extension	1/17/2007	TBC-1022	045394-EP DIV	NIH
2282300	2/24/1998	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to Office Action	1/17/2007	PO27CA	047113-CA	NIH
10/97,127	07/17/2002	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to non-final Office Action	2/2/2007	TBC-1025	046570-CPA2C-US	NIH
2006-53294	2/20/2004	NOVEL INSERTION SITES IN POX VECTORS	Tax Payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST	2/20/2007	P003JP	053627-JP	NIH
4811370.8	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Registration in HK	2/9/2007	P004PCT	053674-EP	NIH
08296385 6001349	ISSUED 02/22/1995	12/14/1999 GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	8th Year Maintenance Fee	06/14/2007 (12/14/1007) EXPIRES	PO10 US	044933-US	NIH
09287221 6319496	ISSUED 4/06/1999	11/20/2001 GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	8th Year Maintenance Fee	05/20/2009 (11/20/2009) EXPIRES	PO10 US	044933-US	NIH
5024096	02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/13/2007 (08/13/2007)	PO10 All	044933-AU	NIH

2,213,451		02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/13/2007 02/13/2008)	POJO CA	044933-CA	NIH
9690706 1.4		02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/28/2007 (08/28/2007)	POJO EP	044933-EP	NIH
H08-525,765		2/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST		POJO JP	044933-JP	NIH
08560,306 6,165,460	ISSUED	07/10/1995	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	8th year Maintenance Fee	06/26/2007 (12/26/2008) EXPIRES 07/10/2015	P030	045394-US	NIH
09/693,121		10/20/2000	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Appeal brief	04/21/2007	P030	045394-CYA 2 C	NIH
2,226,436 ISSUED		06/26/1996	ANTIGEN (PSA) GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (06/26/2008)	US P030 CA	US 045394-CA	NIH
696 1860 12 ISSUED		06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (12/26/2007)	P030 DE	045394-DE	NIH
969234 17.8		06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (12/26/2007)	P030 EP	0-15394-EP	NIH
1113317.5		6/26/1996	GENERATION OF IMMUNE RESPONSE TO PROSTATE SPECIFIC ANTIGEN (PSA)	Response to Office Action	1/17/2007	P030 EP-DV	045394-EP DV	NIH
2103365.7		8/16/2002	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	6/26/2008	P030 HK	045394-I-HK	NIH
9-505834		06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	SEQUENCE LISTING WAS DUE 11/10/2006		P030 JP-DV	045394-JP-DIV	NIH
2006-3 868 1		2/15/2006	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	WAITING FOR RESPONSE FROM IPO - RESPONSE TO OA WAS FILED FEBRUARY 2006		P030 JP	045394-JP	NIH
10/197,127		07/17/2002	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Response to non-final Office Action	02/02/2007	P01 I US	046570-CYA2C-US	NIH

200326471	11/27/2003	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 AU-DV-2	046570-AU DIV 2	NIH
37268/97 ISSUED	07/15/1997	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 AU	046570-AU	NIH
54194/01	07/04/2001	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 AU-DV	046570-AU-DIV	NIH
2.261,989	07/15/1997	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 CA	046570-CA	NIH
97934142.7	07/15/1997	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 EP	046570-EP	NIH
508844/98	7/15/1997	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Response to Office Action	01/03/2007 (04/03/2007, if request is made by 01/03/2007)	P011 JP	046570-JP	NIH
10657,136 ISSUED 7, 118,738	1/25/2002	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	4 <sup>th</sup> year Maintenance Fee	04/12/2010 (10/12/2010) EXPIRES 08/03/2019	P027 US	047113-US	NIH
61860/98	02/24/1998	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Tax payment	02/24/2007 (08/24/2007)	P027 AU	047113-AU	NIH
2.282.300	02/24/1998	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Response to Office Action Tax payment 1	01/17/2007 02/24/2007 (02/24/2008)	P027 CA	047113-CA	NIH
98906706.1	02/24/1998	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Tax Payment	2/24/707 (08/24/2007)	P027 EP	047113-EP	NIH
10660,369	09/11/2003	TRANSJUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1, AND LEA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN-VIVO	Response to non-final OA TRANSFERRED TO E&A ON 11/02/2006	12/20/2006	P037 US STA (NFC)	054440-US	NIH, STANFORD
08/238,611 ISSUED 5,656,465	05/04/1994 08/12/1997	METHODS OF IN VIVO GENE DELIVERY	12 <sup>th</sup> year Maintenance Fee	02/12/2009 (08/12/2009) EXPIRES 08/12/2014	P024 US	042777-US	NIH
25437/95	05/03/1995	METHODS OF IN VIVO GENE DELIVERY	Tax payment	05/03/2007 (11/03/2007)	P024 AU	042777-AU	NIH



2,189,452	05/03/1995	METHODS OF IN VIVO GENE DELIVERY	Tax payment	05/03/2007	P002 CA	042777-CA	NIH
95919744.3	05/03/1995	METHODS OF IN VIVO GENE DELIVERY	Tax payment	05/03/2007	P002 EP	042777-EP	NIH
08270,106 ISSUED 5,698,530	7/1/1994	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	12 <sup>th</sup> year Maintenance Fee	06/16/2009 (12/16/2009)	P002 US	045773-US	NIH
2006092	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment	05/06/2007 (11/06/2007)	P002 AU	046773-AU	NIH
2,102,623	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment	05/06/2007 (05/06/2008)	P002 CA	046773-CA	NIH
92913153 ISSUED UK SE ML MC CHIU DE DK F ES FR GR IT BE AT	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment	05/06/2007 (11/06/2007) EXPIRES 11/06/2012	P002 EP	046773-EP	NIH
4,512,025	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST	05/06/2007 (11/06/2007)	P002 J P	046773-JP	NIH
10543,944	02/20/2004	NOVEL INSERTION SITES IN POX VECTORS	Waiting for 1 <sup>st</sup> OA	-	P003 US	053622-US	NIH
2004291024	02/20/2004	NOVEL INSERTION SITES IN POX VECTORS	Tax Payment and Request for Examination	02/20/2009 (08/20/2009)	P003 AU	053623-AU	NIH
2,515,898	02/20/2004	NOVEL INSERTION SITES IN POX VECTORS	Tax Payment Request for Examination	02/20/2008 (02/20/2009)	P003 CA	053624-CA	NIH
4,817,690	02/20/2004	NOVEL INSERTION SITES IN POX VECTORS	Tax Payment	02/28/2007 (08/28/2007)	P003 EP	053626-EP	NIH
2006-532294	02/20/2004	NOVEL INSERTION SITES IN POX VECTORS	Tax Payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST	2/20/2007	P003 J P	053627-JP	NIH
10579,007	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Waiting for 1 <sup>st</sup> OA	-	P005 US	053666-US	NIH
2004289340	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Tax Payment (05/12/2010)	11/12/2009	P005 AU	5366	NIH
4810831	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Tax Payment	11/30/2006 (05/30/2007)	P005 EP	053663-EP	NIH
2,545,164	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Assignment due	05/05/2007	P005 CA	053664-CA	NIH
2006-539904	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Request for Examination	11/12/2007	P005 J P	053665-JP	NIH
10579,025	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Waiting for 1 <sup>st</sup> OA	-	P004 US	053676-US	NIH



Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-259-1994/2-EIR-00		00/00/00			EIR		00/00/00
E-259-1994/2-PCT-01	PCT/US95/12638	10/02/1995	E-259-1994/0-US-01	08/317,402	PCT-COMB		00/00/00
E-259-1994/2-CA-02	2201592	10/02/1995	E-259-1994/2-PCT-01	08/317,402	PCT		00/00/00
E-259-1994/2-AU-03	39982/95	10/02/1995	E-259-1994/2-PCT-01	08/317,402	PCT	712714	02/24/00
E-259-1994/2-EP-04	95938706.9	10/02/1995	E-259-1994/2-PCT-01	08/317,402	PCT		00/00/00

Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-259-1994/3-EIR-00		00/00/00			EIR		00/00/00
E-259-1994/3-US-01	08/686,280	07/25/1996	E-259-1994/3-EIR-00	08/686,280	ORD		00/00/00
E-259-1994/3-PCT-02	PCT/US97/12203	07/15/1997	E-259-1994/3-US-01	08/686,280	PCT		00/00/00
E-259-1994/3-CA-03	2261989	07/15/1997	E-259-1994/3-PCT-02	08/686,280	PCT		00/00/00
E-259-1994/3-EP-04	97934142.7	07/15/1997	E-259-1994/3-PCT-02	08/686,280	PCT		00/00/00

Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-259-1994/3-JP-05	508844/98	07/15/1997	E-259-1994/3-PCT-02	08/686,280	PCT		00/00/00
E-259-1994/3-AU-06	3726897	07/15/1997	E-259-1994/3-PCT-02	08/686,280	PCT	731860	04/05/01
E-259-1994/3-AU-07	54194/01	07/15/1997	E-259-1994/3-PCT-02	08/686,280	PCT	767562	11/13/03
E-259-1994/3-US-08	10/197,127	07/17/02	E-259-1994/3-US-01	08/686,280	CON		00/00/00

Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-259-1994/4-EIR-00		00/00/00			EIR		00/00/00
E-259-1994/4-US-01	08/686,281	07/25/1996	E-259-1994/4-EIR-00	08/686,281	ORD		00/00/00
E-259-1994/4-PCT-02	PCT/US97/12546	07/09/1997	E-259-1994/4-US-01	08/686,281	PCT		00/00/00
E-259-1994/4-CA-03	2261990	07/09/1997	E-259-1994/4-PCT-02	08/686,281	PCT		00/00/00
E-259-1994/4-EP-04	97933544.5	07/09/1997	E-259-1994/4-PCT-02	08/686,281	PCT		00/00/00
E-259-1994/4-JP-05		07/09/1997	E-259-1994/4-PCT-02	08/686,281	PCT		00/00/00
E-259-1994/4-AU-06	36706/97	07/09/1997	E-259-1994/4-PCT-02	08/686,281	PCT	718945	08/17/00

Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-154-1998/0-EIR-00		00/00/00			EIR		00/00/00
E-154-1998/0-US-01	60/038,253	02/24/1997	E-154-1998/0-EIR-00	60/038,253	PRV		00/00/00
E-154-1998/0-PCT-02	PCT/US98/03693	02/24/1998	E-154-1998/0-US-01	60/038,253	PCT		00/00/00
E-154-1998/0-AU-03	61860/98	02/24/1998	E-154-1998/0-PCT-02	60/038,253	PCT	727308	03/22/01
E-154-1998/0-CA-04	2282300	02/24/1998	E-154-1998/0-PCT-02	60/038,253	PCT		00/00/00
E-154-1998/0-EP-05	98906706.1	02/24/1998	E-154-1998/0-PCT-02	60/038,253	PCT		00/00/00
E-154-1998/0-US-06	09/366,670	08/03/1999	E-154-1998/0-PCT-02	60/038,253	PCT		00/00/00
E-154-1998/0-US-07	10/057,136	01/25/02	E-154-1998/0-US-06	60/038,253	CON		00/00/00

Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-256-1998/0-EIR-00	60/111,582	00/00/00	E-256-1998/0-EIR-00	60/111,582	EIR		00/00/00
E-256-1998/0-US-01	12/09/1998	12/09/1998	E-256-1998/0-US-01	60/111,582	PRV		00/00/00
E-256-1998/0-PCT-02	PCT/US99/26866	11/12/1999	E-256-1998/0-US-01	60/111,582	PCT		00/00/00
E-256-1998/0-AU-03	16218/00	11/12/1999	E-256-1998/0-PCT-02	60/111,582	PCT	774076	05/05/05
E-256-1998/0-EP-04	99958951.8	11/12/1999	E-256-1998/0-PCT-02	60/111,582	PCT		00/00/00
E-256-1998/0-JP-05	2000-588927	11/12/1999	E-256-1998/0-PCT-02	60/111,582	PCT		00/00/00
E-256-1998/0-CA-06	2354024	11/12/1999	E-256-1998/0-PCT-02	60/111,582	PCT		00/00/00
E-256-1998/0-US-07	09/856,988	09/24/01	E-256-1998/0-PCT-02	60/111,582	PCT	6,969,509	11/29/05
E-256-1998/0-US-08	10/406,317	04/04/03	E-256-1998/0-US-07	60/111,582	DIV		00/00/00
E-256-1998/1-EI-R-00		00/00/00			EIR		00/00/00
E-256-1998/1-US-01	11/321,868	12/30/05	E-256-1998/0-US-08	60/111,582	CIP		00/00/00
Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-187-2000/0-EIR-00		00/00/00			EIR		00/00/00
E-187-2000/0-US-01	60/211,717	06/15/00	E-187-2000/0-EIR-00	60/211,717	PRV		00/00/00
E-187-2000/0-PCT-02	PCT/US01/19201	06/15/01	E-187-2000/0-US-01	60/211,717	PCT		00/00/00
E-187-2000/0-US-03	10/297,168	07/16/03	E-187-2000/0-PCT-02	60/211,717	371		00/00/00
E-187-2000/0-EP-04	1946395.9	06/15/01	E-187-2000/0-PCT-02	60/211,717	PCT		00/00/00
E-187-2000/0-CA-05	2412050	06/15/01	E-187-2000/0-PCT-02	60/211,717	PCT		00/00/00
E-187-2000/0-AU-06	2001268452	06/15/01	E-187-2000/0-PCT-02	60/211,717	PCT		00/00/00
E-187-2000/0-JP-07	2002-510097	06/15/01	E-187-2000/0-PCT-02	60/211,717	PCT		00/00/00
E-187-2000/0-HK-08	3105875.5	08/21/03	E-187-2000/0-EP-04	60/211,717	PCT		00/00/00
Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-087-2005/0-EIR-00		00/00/00			EIR		00/00/00
E-087-2005/0-US-01	60/519,354	11/12/03	E-087-2005/0-EIR-00	60/519,354	PRV		00/00/00
E-087-2005/0-PCT-02	PCT/US2004/38643	11/12/04	E-087-2005/0-US-01	60/519,354	PCT		00/00/00
E-087-2005/0-US-03	10/579,025	05/11/06	E-087-2005/0-PCT-02	60/519,354	119		00/00/00
E-087-2005/0-AU-04	2004289368	11/12/04	E-087-2005/0-PCT-02	60/519,354	PCT		00/00/00
E-087-2005/0-CA-05		11/12/04	E-087-2005/0-PCT-02	60/519,354	PCT		00/00/00
E-087-2005/0-EP-06	4811370.8	11/12/04	E-087-2005/0-PCT-02	60/519,354	PCT		00/00/00
E-087-2005/0-JP-07		11/12/04	E-087-2005/0-PCT-02	60/519,354	PCT		00/00/00
E-088-2005/0-EIR-00		00/00/00			EIR		00/00/00
E-088-2005/0-US-01	60/519,427	11/12/03	E-088-2005/0-EIR-00	60/519,427	PRV		00/00/00
E-088-2005/0-PCT-02	PCT/US2004/037610	11/12/04	E-088-2005/0-US-01	60/519,427	PCT		00/00/00
E-088-2005/0-US-03	00/000,000	05/11/06	E-088-2005/0-PCT-02	60/519,427	119		00/00/00
E-088-2005/0-AU-04	2004289340	11/12/04	E-088-2005/0-PCT-02	60/519,427	PCT		00/00/00
E-088-2005/0-CA-05	2,545,164	11/12/04	E-088-2005/0-PCT-02	60/519,427	PCT		00/00/00
E-088-2005/0-EP-06	4810831	11/12/04	E-088-2005/0-PCT-02	60/519,427	PCT		00/00/00

E-088-2005/0-JP-07		11/12/04	E-088-2005/0-PCT-02	60/519,427	PCT	00/00/00
E-028-2007/0-EIR-00		00/00/00			EIR	00/00/00
E-028-2007/0-US-01	60/448,591	02/20/03	E-028-2007/0-EIR-00	60/448,591	PRV	00/00/00
E-028-2007/0-PCT-02	PCT/US2004/00507 7	02/20/04	E-028-2007/0-US-01	60/448,591	PCT	00/00/00
E-028-2007/0-JP-03		00/00/00	E-028-2007/0-PCT-02		PCT	00/00/00

E-320-2005/0-US-02	10/660,369	09/11/03	E-320-2005/0-US-01	60/410,161	111	00/00/00
--------------------	------------	----------	--------------------	------------	-----	----------

[Empty box]